Dapagliflozin
Idiopathic Pulmonary Fibrosis
Clinical trials
3
Developer
National Heart, Lung, and Blood Institute (NHLBI)
Overview
Dapagliflozin is an agent tracked by PF-Atlas in the context of idiopathic pulmonary fibrosis. It appears in 3 tracked IPF clinical trials.
Dapagliflozin clinical trials
Explore related
Medical disclaimer. This page summarizes research about Dapagliflozin for information only. It is not medical advice. Verify approval status and evidence with the FDA and a pulmonologist.